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THERAPEUTIC CYCLOSPORINE (CSA) MONITORING AFTER ALLOGE-
NEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): HIGH-
PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) OR TDX?
Triﬁlio, S., Borensztajn, J., Mehta, J. Northwestern Memorial Hospital,
Chicago.
CsA level ranges for GVHD prophylaxis have been developed
based on HPLC which estimates the parent (active) drug, but is
cumbersome. TDx, a monoclonal antibody assay for CsA, is
quicker but also measures some of the metabolites which are
biologically inactive. An internal feasibility study was done to
consider switching from HPLC to TDx. 72 blood samples from 6
HSCT recipients (5-19 each) submitted for routine HPLC testing
were also subjected to TDx. There was no charge for TDx. Only
HPLC results were available for clinical use. There was strong
correlation between HPLC and TDx results for the whole group
(r  0.92; P  1029), and for each patient individually (r 
0.75-0.99; P  0.002 to 108). The regression model was:
HPLC  0.55TDx-14.38. The mean (SD) TDx and HPLC levels
were 675 (251) and 359 (149). The TDx/HPLC ratio was 1.34-
2.67 (median 1.92). There was no relationship between the TDx/
HPLC ratio and time from starting CsA, BUN, creatinine, biliru-
bin, albumin, ALT, AST, or alkaline phosphatase. When HPLC
was calculated (c-HPLC) from TDx using a simpliﬁed bedside
formula (c-HPLC  TDx/1.9), the difference between c-HPLC
and actual HPLC (a-HPLC) was -29% to 41% (median 1%).
51% of the paired readings differed by10%, and 14% by20%.
Assuming 200-400 as the therapeutic range, 31 a-HPLC readings
required dose adjustment (8 increase, 23 decrease) compared with
28 c-HPLC (6 increase, 22 decrease). Actions (increase, decrease,
or no change) suggested by a-HPLC and c-HPLC were concor-
dant in 59 cases and discordant in 13 (18%). Discordance was
deﬁned as “potentially critical” (change suggested by a-HPLC but
no change suggested by c-HPLC) in 8 instances, and “not critical”
in 5 (change suggested by c-HPLC and no change suggested by
a-HPLC; where a % change in c-HPLC towards normal when
applied to a-HPLC would not have resulted in a-HPLC going out
of the therapeutic range). Our data show that while there is con-
siderable intra-patient variability in the TDx/HPLC ratio, the
correlation between HPLC and TDx is very strong. TDx can be
substituted for HPLC with a sutiable modiﬁcation in the therapetic
range (380-760 here). Using TDx in our practice is unlikely to
result in the CsA level deviating from the therapeutic range most
of the time; including in patients with severe liver and/or kidney
dysfunction. It must be emphasized that in practice, therapeutic
CsA monitoring usually plays a secondary role to the clinical
picture (evidence of drug toxicity and GVHD).
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TACROLIMUS (FK-506) AND MYCOPHENOLATE MOFETIL (MMF) GVHD
PROPHYLAXIS IN PEDIATRIC ALLOGENEIC SCT (ALLOSCT) RECIPI-
ENTS: ALTERED MMF PHARMACOKINETICS (PK) ASSOCIATED WITH
ACUTE (A)GVHD
Bessmertny, O., Farris, K., van de Ven, C., Harrison, L., Osunkwo, I.,
Wolownik, K., Garvin, J., George, D., Del Toro, G., Bradley, M.B.,
Cheung, Y.-K., Skerrett, D., Cairo, M.S. Children’s Hospital of New
York-Presbyterian, Columbia University, New York, NY.
FK-506/MMF is an effective salvage therapy for steroid-refrac-
tory chronic (C)GVHD (Mookerjee et al, BMT:24:517, 1999) and
prophylaxis of A and CGVHD following nonmyeloablative and
fully ablative conditioning in adults (Rini et al, JCO, 2002; Pavletic
et al Blood, 2002; McSweeney et al, Blood, 2002). We investigated
the safety and efﬁcacy of a FK-506/MMF regimen for AGVHD
prophylaxis in 47 patients (mean age 8.5 yrs [range 0.5-21 yrs]; 31
M, 16 F) undergoing 51 AlloSCTs for hematologic malignancies
(n  27), non-malignant disorders (n  16), and neuroblastoma
(n  4). FK-506 was given 0.03 mg/kg/day continuous IV on Day
-1 or 1st day of conditioning plus MMF 15 mg/kg/dose PO/IV
BID starting Day 1. Doses were adjusted to maintain trough
steady state concentrations within reference ranges of 5-20 ng/mL
for FK-506 and 1-3.5 mcg/mL for mycophenoleic acid (MPA).
HLA typing was low resolution for A, B and C and high resolution
for DR alleles. Stem cell sources: 6/6 UCB (n  4), 6/6 related (R)
UCB (n  1), 5/6 UCB (mismatch: class I [n  8]), 4/6 UCB
(mismatch: class I [n  9], class II [n  2], class I/II [n  8]), 6/6
RBM (n 6), 5/6 RBM (mismatch: class I [n 1], class II [n 1]),
6/6 RPBSCT (n  10), 10/10 unrelated PBSCT (n  1). Condi-
tioning types were: reduced intensity (n  25) and myeloablative
(n  26). Mean time to ANC 500/mm3 x 2 days (n  42) was
13.8  1.7 days and 25.9  17 days following RPBSCT/BM and
UCB, respectively. Mean time to platelet engraftment (20K/
mm3 x 7 days) was 14.7 6 days for RPBSCT/BM and 61.3 57.7
days for UCB recipients. Mean follow up was 324 days (17-989).
Among 39 evaluable transplants, Kaplan-Meier probability of de-
veloping grade II AGVHD was 43.7  8% (36.1  10.4% for
UCB and 56.2  12.4% for MFD recipients) and CGVHD was
38  20% at 18 mos. FK-506/MMF were well tolerated, with 1
episode of grade IV hyperglycemia and 3 episodes of grade III-IV
neurotoxicity. Probability of 1-year OS was 56  12%. Probability
of developing grade II AGVHD was 36.2  13.1% for patients
who achieved MPA trough 1 mcg/mL prior to Day 30 vs
85.7  13.2% for those who did not (p  0.017). These results
suggest that FK506/MMF is a safe and effective GVHD prophy-
laxis regimen following related and unrelated AlloSCT in children.
Subtherapeutic MPA trough concentrations are associated with a
signiﬁcantly increased incidence of grade II AGVHD. Further
MMF pharmacokinetic/pharmacodynamic studies are ongoing in
pediatric AlloSCT recipients to deﬁne the optimal dose and sched-
ule of MMF.
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SHOULD SERUM VORICONAZOLE (VORI) LEVELS BE MONITORED IN
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) RE-
CIPIENTS?
Triﬁlio, S.1, Ortiz, R.1, Pennick, G.2, Pi, J.1, Verma, A.1, Mehta, J.1
1. Northwestern University, Chicago; 2. UT Health Science Center, San
Antonio.
Vori has signiﬁcant activity against Candida and Aspergillus. It is
metabolized by the hepatic cytochrome P450 enzymes 2C19, 2C9
and 3A4. CYP2C19, which plays a signiﬁcant role in the metabo-
lism, exhibits signiﬁcant genetic polymorphism. As a result, some
patients metabolize Vori poorly. The clinical signiﬁcance of this
and resultant possible increases in Vori levels is unknown, and the
utility of monitoring Vori levels is unclear. We monitored steady-
state trough serum Vori levels in 22 allogeneic HSCT recipients
using a new HPLC assay (Pennick et al. Antimicrob Agents Che-
mother 2003;47:2348-50). All had received non-myeloablative
conditioning with 100 mg/m2 melphalan (50 mg/kg cyclophos-
phamide if not prior autograft). GVHD prophylaxis comprised
cyclosporine/tacrolimus with mycophenolate mofetil. Vori was
started at 200 mg BID PO in 20 patients, and 400 mg BID for a day
followed by 200 mg BID in 2. One had aspergillosis, and the rest
were receiving Vori prophylactically or empirically. Patients had
drug levels checked once (n  12), twice (n  8), or 3 times (n 
2); 5 days to 9 months (median 10 days) after starting Vori or dose
modiﬁcation. The intention was to achieve a level greater than
0.5-1.0 g/mL corresponding to the in vitro MIC90 of Vori for
Aspergillus spp. The 22 baseline levels ranged from 0.2 to 6.8
g/mL (median 1.1). Overall, the 36 levels were 0.2-6.8 (median
1.7); with 5 levels 0.5. An increase in the dose to 300 mg twice
daily in 3 patients (2 with levels0.5 and 1 with a level of 1.0 in the
presence of aspergillosis) increased the level 6- to 8-fold. There
was no signiﬁcant correlation between Vori levels and serum cre-
atinine, bilirubin, and ALT. Vori levels correlated with alkaline
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